SCHEMBL1840174

SCHEMBL1840174

CN(C)c1ccnc2[nH]nc(-c3ccnc(O)c3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.38
ROCK1 Q13464 1/20 0.38
CDC42BPA Q5VT25 1/20 0.38
CDC42BPB Q9Y5S2 1/20 0.38
LRRK2 Q5S007 9/20 0.35
CDC7 O00311 1/20 0.34
MAP4K4 O95819 1/20 0.34
PIM1 P11309 1/20 0.34
PRKACA P17612 1/20 0.34
CDK2 P24941 1/20 0.34
GSK3B P49841 1/20 0.34
CDK7 P50613 1/20 0.34
CDK9 P50750 1/20 0.34
HIPK2 Q9H2X6 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 2/20 0.31
MAPK1 P28482 5/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13521503 0.85 MAPK1 (0.41) ROCK2ROCK1CDC42BPACDC42BPBLRRK2
SCHEMBL1838682 0.84 LRRK2 (0.43) ROCK2ROCK1CDC42BPACDC42BPBLRRK2
SCHEMBL2239866 0.78 ROCK2 (0.39) ROCK2ROCK1CDC42BPACDC42BPBLRRK2
SCHEMBL1838201 0.73 CDK2 (0.40) ROCK2ROCK1CDC42BPACDC42BPBCDC7
SCHEMBL16688589 0.70 ROCK2 (0.47) ROCK2ROCK1CDC42BPACDC42BPBCDC7
SCHEMBL1840200 0.70 ROCK2 (0.45) ROCK2ROCK1CDC42BPACDC42BPBCDC7
SCHEMBL1841531 0.67 LRRK2 (0.43) ROCK2LRRK2CDC7MAP4K4PIM1
SCHEMBL22275989 0.61 MAP4K4 (0.49) LRRK2MAP4K4MAPK1
SCHEMBL16025869 0.61 MKNK1 (0.48) LRRK2MAPK1
SCHEMBL1839780 0.61 MAPK1 (0.43) LRRK2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN disclosed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 ROCK2 1231/4885ROCK1 759/4885CDC42BPA 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.